Last reviewed · How we verify
Apetiviton BC
Apetiviton BC is a drug that works by inhibiting the action of a specific enzyme.
Apetiviton BC is a drug that works by inhibiting the action of a specific enzyme. Used for Type 2 diabetes.
At a glance
| Generic name | Apetiviton BC |
|---|---|
| Also known as | Petivit Bc |
| Sponsor | Cifarma Cientifica Farmaceutica Ltda |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action of Apetiviton BC is not well understood, but it is believed to involve the inhibition of a key enzyme involved in the regulation of blood sugar levels. This inhibition leads to a decrease in blood sugar levels, which can help to manage diabetes. Further research is needed to fully understand the mechanism of action of Apetiviton BC.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apetiviton BC CI brief — competitive landscape report
- Apetiviton BC updates RSS · CI watch RSS
- Cifarma Cientifica Farmaceutica Ltda portfolio CI